ACADIA Pharmaceuticals Inc

Most Recent

  • uploads///Part  Graph
    Company & Industry Overviews

    Analyzing IBB’s Moving Averages

    As of June 13, 33% of IBB’s stocks were trading above their 20-day moving averages and 43% were trading above their 50-day moving averages.

    By Peter Neil
  • uploads///Opko Health analysts
    Earnings Report

    Opko Health: Q2 Expenditures, Developments, Recommendations

    Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.

    By Daniel Collins
  • uploads///Graph Part  OCt
    Company & Industry Overviews

    IMMU and ACRX Outperform in the Biotech Downdraft

    Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. The stock closed at $2.08.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02

    Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.

    By Peter Neil
  • uploads///medications _
    Company & Industry Overviews

    Acadia Pharma Moves Up on FDA Approval

    Today, Acadia Pharmaceuticals (ACAD) is trending higher on news of the FDA’s approval of a 34 mg capsule and 10 mg tablet of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis-related hallucinations and delusions.

    By Sarah Collins
  • uploads///Part  chart
    Company & Industry Overviews

    ANAC Leads Pharmaceuticals Valuations in the Week Ending July 17

    Anacor Pharmaceuticals (ANAC) with a 71.92% jump in its price for the week ending July 17, 2015, has helped to push the average PVB of the pharmaceutical sector to 11.62.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Biotechnology ETFs: Who Were the Top Performers Last Week?

    Biotechnology ETFs rose during the week ending April 1, 2016. The SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology ETF (IBB) rose 6.2% and 5.0%, respectively.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Anacor Stayed Positive among the Hammered Mid-Caps

    Anacor Pharmaceuticals (ANAC) was one of the top mid-cap performers for the week. It rose by 5.9% for the week. The stock rose due to good trading volumes.

    By Peter Neil
  • uploads///AdobeStock_
    Company & Industry Overviews

    Why Is Acadia Pharmaceuticals Falling Today?

    Yesterday, Acadia Pharmaceuticals reported top-line results from its phase three trial evaluating Nuplazid in schizophrenia.

    By Margaret Patrick
  • uploads///Spectrum net loss
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.

    By Daniel Collins
  • uploads///Portola
    Company & Industry Overviews

    A Look at Portola Pharmaceuticals’ Financial Performance

    Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

    By Daniel Collins
  • uploads///Axovant ana reco
    Company & Industry Overviews

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”

    By Kenneth Smith
  • uploads///Opko Health
    Earnings Report

    How Opko Health Fared in the Second Quarter of 2018

    Opko Health (OPK) generated net revenues of $263.7 million in the second quarter of 2018 compared to $292.6 million in Q2 of 2017.

    By Daniel Collins
  • uploads///ACAD
    Company & Industry Overviews

    Exploring Acadia Pharmaceuticals’ Promising Research Pipeline

    Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.

    By Kenneth Smith
  • uploads///bacteria _
    Company & Industry Overviews

    What Analysts Thought of Ligand Pharmaceuticals in June

    Two of the six analysts covering Ligand Pharmaceuticals in June gave the stock “strong buy” ratings, and four gave it “buy” ratings.

    By Kenneth Smith
  • uploads///Fei
    Company & Industry Overviews

    Why Axovant Sciences Stock Rose in Week Ended June 8

    On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid for Long-Term Care: Revenue Driver for Acadia?

    Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid Sees Increasing Physician Intent to Prescribe in 2017

    Acadia Pharmaceuticals’ (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid Expected to Become a Leading Central Nervous System Drug

    On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Holdings: What’s the Trend in Its Moving Averages?

    On June 15, 2016, XBI closed at $54.74. It was trading above its 20-day and 50-day moving averages. XBI’s 20-day moving average is $56.30.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Investors Not Impressed with Immunomedics’ IMMU-132 Study

    On June 6, 2016, biotech stocks continued their upward trend and appeared to be in a positive, consolidating mood. IBB rose 1.5% that day.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue

    Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes

    Anacor Pharmaceuticals rose 7.8% and closed at $61.51 on April 4, 2016. It was trading above its 20-day moving average. Year-to-date, the stock has fallen 45.6%.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Mid-Cap News: Look Who Took a Beating on March 23

    Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.

    By Peter Neil
  • uploads///Graph Part  Nov
    Earnings Report

    ISIS Leads the Mid-Cap Space, Stock Rises by 12.3%

    ISIS Pharmaceuticals rose by 12.3% as it announced 3Q15 earnings. ISIS reported revenue of $49.1 million as compared to $44.1 million in 3Q14.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Myriad Genetics: Top Performer in the Biotechnology Subgroup

    Myriad Genetics (MYGN) rose 9% on November 4, 2015. It reported its fiscal 1Q16 results. Myriad Genetics reported revenue of $183.5 million.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps

    In the small-cap space, the top ten stocks of XBI had an average return of -12.18% for the week ended September 25, 2015. This is similar to XBI’s top ten large-cap stocks that returned -12.15%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    ENDP Traded above 100-Day Moving Average in Week to September 18

    ENDO International (ENDP) rose 9.52%. The stock went up on high trading volumes during September 16-18.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Dyax Traded above Its 100-Day Moving Average

    Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI Stocks: 33% Are Trading above the 20-Day Moving Averages

    XBI fell substantially in the moving averages. From August 10–17, 2015, only 32.63% of the stocks were trading above the 20-day moving averages.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Pharmaceutical Stocks Affect the iShares NASDAQ Biotechnology ETF

    Out of 62 stocks held within the pharmaceutical subgroup of the iShares NASDAQ Biotechnology ETF (IBB), 49 stocks fell during the week ending August 7, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    IBB ETF Pounded by Biotech and Pharma Subgroups in Early August

    The biotechnology and pharmaceutical subgroups comprise 97.43% of the iShares NASDAQ Biotechnology ETF (IBB) portfolio.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Anacor Pharmaceuticals Outperforms the Market

    Within IBB, stocks like Receptos and Celgene performed well. However, Anacor Pharmaceuticals outperformed everyone with an eye-catching 71.92% for the week ending July 17.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.